Theorist position for analysis b7f886d9-da3f-4e0d-a8a8-9c262e268796: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra
Source basis: Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease (Molecular Psychiatry, 2024, DOI 10.1038/s41380-024-02574-w). The stored gap context says: Multi-omics analysis implicated m6A modification in PD risk but the causal downstream mechanism on alpha-synuclein biology was not established.
Primary hypothesis: m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics is not merely an associated signature; it is a testable mechanism that can explain the open question: How does N6-methyladenosine (m6A) RNA modification alter alpha-synuclein mRNA stability and protein aggregation kinetics in substantia nigra dopaminergic neurons, and can pharmacological manipulation of m6A writers/erasers reduce Lewy body formation in PD model systems?
Three candidate claims should be carried forward. First, the strongest causal signal should appear in the cell type or tissue compartment named by the question, not only in bulk disease contrasts. Second, perturbing the axis should shift a proximal molecular phenotype before it shifts a late pathology phenotype, which would help separate cause from consequence. Third, the relevant readout should be stratified by m6A, RNA, N6-, alpha-synuclein, because collapsing across those terms would erase the mechanism the analysis is trying to test.
The priority experiment is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays. A positive result would require concordance across human observational data, disease-relevant cellular models, and at least one perturbation that moves the predicted proximal readout in the expected direction.